The FDA expanded approval of talazoparib plus enzalutamide to HRR-mutated metastatic androgen pathway modulation-naïve or -sensitive prostate cancer following a significant radiographic PFS benefit in TALAPRO-3.
|Articles|February 15, 2021
Pharmacy Times: Week of February 15 Lineup
This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.
Advertisement
This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week, including:
- A video interview with Susan Swindells, MD, a professor in the Department of Internal Medicine and Medical Director in the Specialty Care Clinic at the University of Nebraska Medical Center, on a once-monthly, long-acting regimen for HIV recently approved by the FDA and how it will impact care for patients with HIV.
- A new episode of Pharmacy Focus that discusses performance measures in pharmacy and leadership techniques for pharmacists with Jesse McCullough.
- An article that provides an overview on the importance of sleep in infant children. Studies have shown that sleep benefits infants’ memories and general cognitive and emotional development.
Advertisement
Related to this article
Pharmacists can help care for patients receiving breast cancer endocrine therapy by identifying fracture risk early and supporting appropriate bone-directed treatment throughout survivorship.
Hiddo J. L. Heerspink, PharmD, PhD, discusses SOLSTICE elecoglipron data, finerenone in FSGS, and glucagon’s kidney effects from ASN Kidney Week 2026.
A current pharmacy resident provides insights on how pharmacy students can manage the transition from student to resident.
Pharmacy performance measures should recognize clinical interventions, patient counseling, prescriber collaboration, and outcomes—not prescription volume alone.
CMS’s GLP-1 Bridge demo bypasses Part D to cover select obesity drugs, with a $50 monthly copay, PA workflow, and strict eligibility through 2027.
Two Kidney Week 2026 analyses tie SGLT2 inhibitors to kidney, CV, and survival gains in T2D, yet over half of patients with diabetic CKD receive neither.
Two Kidney Week 2026 abstracts show a dose-response link between cardiovascular-kidney-metabolic syndrome (CKM) stage and chronic kidney disease (CKD), while primary care clinicians cite evidence and workflow barriers.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Beyond Prescription Volume: Measuring the Pharmacist’s Value
2
Medicare GLP-1 Bridge Runs Outside Part D and Pharmacy Teams Need a Different Workflow
3
SGLT2 Inhibitors Benefit Frail Adults With T2D, Remain Underused
4
Why Drug Dosing in Acute Kidney Injury Is So Hard to Get Right
5